What's new? This blog keeps you up-to-date with the latest news, events and campaigns at OLS.

Recording available: How the Curiox Laminar Wash HT1000 System improves the workflow at the flow cytometry core facility Linköping University, Sweden


In this webinar we present a unique live cell assay which allows label-free and continuous tracking of CPE progression in virus-infected cells, providing a dramatically simplified workflow for diverse virology assays


upgrade your scratch assay


+ xCELLigence Protocols, Tips & Tricks +
Evaluating Drug-Mediated Cytotoxicity in Real Time


In this webinar, viewers will have the chance to learn about tools and recent developments in flow cytometry that simplify assay design and workflow.


Join ACEA's global flow cytometry webinar featuring renowned speakers, namely Paul Wallace (Roswell Park Cancer Institute, President of CYTO), Bill Telford (NIH/NCI), and Chris Groves (MedImmune) and learn the latest instrumentation and application news related to flow cytometry.


Webinar NovoCyte Flow Cytometry

November 17: We will present the importance of studying free radicals, their dual roles as both toxic and beneficial compounds in cellular response and immune function. We will also introduce a new panel of multicolor CytoTell™ cell proliferation and tracking dyes that are well excited by major NovoCyte laser lines.


Register now for our webinar "Sensitive Yet Realistic Assessment of CAR T Cell Killing Capacity Against Solid Tumors"


Evaluating Drug-Induced Proarrhythmic Risk Using the CardioECR System
Wednesday, March 11, 2015
16:00 CET


Sehen Sie jetzt das Webinar von Dr. Bohne vom 10.12.2014 "on demand".


Vor dem Webinar nächste Woche mit ACEA Biosciences beantwortet Dr. Bohne Fragen zu seinen Erfahrungen mit xCELLigence Zell-Analyzern.
Before the webinar next week with ACEA Biosciences Dr. Bohne answered questions about his experience with xCELLigence cell analyzers.


In diesem Webinar mit ACEA Biosciences wird Dr. Felix Bohne vom Helmholtz Zentrum München darstellen wie bi-spezifische Antikörperkonstrukte als vielversprechender immunotherapeutischer Ansatz gegen chronische Hepatitis B eingesetzt werden können.

1 2 >
Seite 1 von 2